Zydus Cadila gets USFDA nod to market Fingolimod capsules, Verapamil Hydrochloride Injection

Zydus Cadila has received final approval from the United States Food
and Drug Administration (USFDA) to market Fingolimod capsules,
(Gilenya) in the strengths of 0.5 mg, Zydus Cadila, part of Cadila
Healthcare group, said in a regulatory filing.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-usfda-nod-to-market-fingolimod-capsules-verapamil-hydrochloride-injection/articleshow/78716968.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment